Center-Authored Papers

Filters: Author is Hirsch, Fred R  [Clear All Filters]
Journal Article
Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR.  2012.  Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD et al..  2015.  Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(7):1514-24. Abstract
West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J et al..  2017.  Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials.. Clinical lung cancer. Abstract
Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES et al..  2010.  Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(31):4747-54. Abstract
Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV et al..  2013.  Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer: SWOG S0536.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Abstract
Chen Y, Moon J, Pandya KJ, Lau DHM, Kelly K, Hirsch FR, Gaspar LE, Redman M, Gandara DR.  2013.  A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer.. Frontiers in oncology. 3:219. Abstract
Gandara DR, Redman M, Hirsch FR.  2015.  Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.. JAMA oncology. :1-2.
Hirsch FR, Kabbinavar F, Eisen T, Martins RG, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW et al..  2011.  A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(26):3567-3573. Abstract
Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan UA, McWilliams A, Tsao MS et al..  2016.  Scientific Advances in Lung Cancer 2015.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Abstract
Bunn PA, Minna J, Augustyn A, Gazdar A, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP et al..  2016.  Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes? Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 11(4):453-74.
Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley J et al..  2008.  Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 3(9):1026-31. Abstract
Lau DHM, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, Redman MW, Gandara DR.  2013.  Southwestern Oncology Group Phase II Trial (S0526) of Pemetrexed in Bronchioloalveolar Carcinoma Subtypes of Advanced Adenocarcinoma.. Clinical lung cancer. Abstract
Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR.  2015.  SWOG S0709: Randomized Phase II Trial of Erlotinib Versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Abstract